---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-073905"
form_type: "8-K"
ticker: null
cik: "0001907685"
company_name: "Comera Life Sciences Holdings, Inc."
filed_at: "2023-12-29T23:59:59+00:00"
generated_at: "2026-06-07T06:07:32.419099+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Comera Life Sciences raises $1.5M via 12% senior secured convertible notes due 2024 with warrants

## Summary
- $1.5M aggregate principal of 12.0% Senior Secured Convertible Notes due Dec 29, 2024; convertible at $0.055/share, interest payable monthly.
- Warrants issued for 200% of Note Shares, exercisable immediately at $0.055/share for 5 years.
- Purchasers include existing major stockholders Charles Cherington and trusts controlled by David Soane (each >20% prior).
- Purchasers granted Share Purchase right to buy all outstanding stock at $0.0825 or 1.5x closing price; exclusivity through Dec 2024.
- Notes secured by first priority lien on substantially all assets; subject to affirmative/negative covenants.

## SEC filing metadata
- accession: 0000950170-23-073905
- form_type: 8-K
- cik: 0001907685
- company_name: Comera Life Sciences Holdings, Inc.
- filed_at: 2023-12-29T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907685/000095017023073905/0000950170-23-073905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907685/000095017023073905/cmra-20231229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-073905
- JSON: https://secwatch.observer/filing/0000950170-23-073905.json
- Plain text: https://secwatch.observer/filing/0000950170-23-073905.txt

## Key facts
- Debt Financings
  Comera Life Sciences Holdings, Inc. incurred senior notes of $1,500,000 in aggregate principal amount with certain purchasers at 12.0% maturing December 29, 2024.
  - Instrument: senior notes
  - Principal: $1,500,000 in aggregate principal amount
  - Counterparty: certain purchasers
  - Rate: 12.0%
  - Maturity: December 29, 2024
  - Event: incurrence
  source text: $1,500,000 in aggregate principal amount of 12.0% Senior Secured Convertible Notes due 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907685/000095017023073905/0000950170-23-073905-index.htm
- Material Agreements
  Comera Life Sciences Holdings, Inc. entered into Securities Purchase Agreement with certain purchasers valued at $1,500,000 (effective 2023-12-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain purchasers
  - Value: $1,500,000
  - Effective: 2023-12-29
  source text: On December 29, 2023, Comera Life Sciences Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain purchasers described below (collectively, the “Purchasers” and each, a “Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) $1,500,000 in aggregate principal amount of 12.0% Senior Secured Convertible Notes due 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907685/000095017023073905/0000950170-23-073905-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.